Your search returned 13 results.

Results
	1.	Reply to a. Avan et Al. MedStar authors: Swain, Sandra M PMID: 25870094 Year: 2015 Citation: Journal of Clinical Oncology. 33(15):1712, 2015 May 20. Institution: Washington Cancer Institute Medline publication type: Comment Letter Form of publication: Journal Article All authors: Baselga J, Clark E, Kiermaier A, Swain S DOI: http://dx.doi.org/10.1200/JCO.2015.60.8398 Add to cart (remove)
	2.	Pertuzumab: increasing the options. MedStar authors: Nunes, Raquel Swain, Sandra M PMID: 24855727 Citation: Oncology (Williston Park). 28(3):199, 204, 210, 2014 Mar. Institution: Washington Cancer Institute Medline publication type: Comment Journal Article Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Nunes R, Swain SM Add to cart (remove)
	3.	Pertuzumab for the treatment of breast cancer. [Review] MedStar authors: Lynce, Filipa Swain, Sandra M PMID: 24921704 Year: 2014 Citation: Cancer Investigation. 32(8):430-8, 2014 Oct. Institution: Washington Cancer Institute Medline publication type: Journal Article Research Support, Non-U.S. Gov't Review Form of publication: Journal Article All authors: Lynce F, Swain SM DOI: http://dx.doi.org/10.3109/07357907.2014.922570 Add to cart (remove)
	4.	Pertuzumab for the treatment of breast cancer: a safety review. [Review] MedStar authors: Swain, Sandra M PMID: 26982349 Year: 2016 Citation: Expert Opinion on Drug Safety. 15(6):853-63, 2016 Jun Institution: Washington Cancer Institute Medline publication type: Journal Article Review Form of publication: Journal Article All authors: Gao J, Swain SM DOI: https://dx.doi.org/10.1517/14740338.2016.1167185 Add to cart (remove)
	5.	Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. MedStar authors: Swain, Sandra M PMID: 23475636 Year: 2013 Citation: Oncologist. 18(3):257-64, 2013. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Amadori D, Baselga J, Benyunes MC, Clark E, Cortes J, Ewer MS, Knott A, Miles D, Ross G, Swain SM DOI: http://dx.doi.org/10.1634/theoncologist.2012-0448 Add to cart (remove)
	6.	Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. MedStar authors: Swain, Sandra M PMID: 25332247 Year: 2014 Citation: Journal of Clinical Oncology. 32(33):3753-61, 2014 Nov 20. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Clark E, Cortes J, Im SA, Kiermaier A, Ross G, Swain SM DOI: http://dx.doi.org/10.1200/JCO.2013.54.5384 Add to cart (remove)
	7.	Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. MedStar authors: Swain, Sandra M PMID: 24262440 Year: 2013 Citation: Journal of the National Cancer Institute. 105(23):1782-8, 2013 Dec 4. Institution: Washington Cancer Institute Medline publication type: Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Bandos H, Blackmon NL, Bohn OL, Burandt E, Costantino JP, Fehrenbacher L, Fumagalli D, Gavin PG, Geyer CE Jr, Goldstein LC, Horne ZD, Jeong JH, Kim C, Kim SI, Kim SR, Lee A, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Reilly ML, Remillard MY, Romond EH, Sneige N, Swain SM, Tanaka N, Taniyama Y, Wickerham DL, Wolmark N DOI: http://dx.doi.org/10.1093/jnci/djt321 Add to cart (remove)
	8.	Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. MedStar authors: Swain, Sandra M PMID: 23868905 Year: 2013 Citation: Annals of Oncology. 24(10):2630-5, 2013 Oct. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Clark E, Cortes J, Im SA, Im YH, Knott A, Pivot X, Ross G, Swain SM DOI: http://dx.doi.org/10.1093/annonc/mdt274 Add to cart (remove)
	9.	Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. [Review] MedStar authors: Swain, Sandra M PMID: 23530718 Year: 2013 Citation: Expert Opinion on Biological Therapy. 13(5):779-90, 2013 May. Institution: Washington Cancer Institute Medline publication type: Journal Article Research Support, Non-U.S. Gov't Review Form of publication: Journal Article All authors: O'Sullivan CC, Swain SM DOI: http://dx.doi.org/10.1517/14712598.2013.783007 Add to cart (remove)
	10.	Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. MedStar authors: Swain, Sandra M PMID: 23969513 Year: 2013 Citation: Anti-Cancer Drugs. 24(10):1084-92, 2013 Nov. Institution: Washington Cancer Institute Medline publication type: Journal Article Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Brewster M, Cortes J, Garg A, Grincuka E, Hauschild M, Kudaba I, Lum BL, Marier JF, Masuda N, McNally V, Nijem I, Patel T, Ross G, Swain SM, Trinh MM, Visich J DOI: http://dx.doi.org/10.1097/CAD.0000000000000016 Add to cart (remove)
	11.	Avastin withdrawal symptoms. MedStar authors: Lynce, Filipa Swain, Sandra M PMID: 22263961 Citation: Expert Opinion on Pharmacotherapy. 13(3):293-8, 2012 Feb. Institution: Washington Cancer Institute Medline publication type: Editorial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Lynce F, Swain SM DOI: http://dx.doi.org/10.1517/14656566.2012.652088 Add to cart (remove)
	12.	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. MedStar authors: Swain, Sandra M PMID: 34890214 Year: 2022 Citation: Journal of Clinical Oncology. 40(5):438-448, 2022 02 10. Department: Associate Dean for Research Development Medline publication type: Journal Article Form of publication: Journal Article All authors: Barrios C, Bonnefoi H, Boulet T, De Laurentiis M, Ellis PA, Fehrenbacher L, Gianni L, Gralow J, Harbeck N, Huang CS, Im SA, Im YH, Ito Y, Krop IE, Liu H, Macharia H, Nowecki Z, Shah J, Song C, Swain SM, Toi M, Trask P, Winer EP DOI: https://dx.doi.org/10.1200/JCO.21.00896 Add to cart (remove)
	13.	Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. MedStar authors: Swain, Sandra M PMID: 23685835 Year: 2013 Citation: Clinical Cancer Research. 19(13):3681-92, 2013 Jul 1. Institution: Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Bais C, Brauer MJ, Chen D, Cheng JH, Chung AS, Clermont AC, Ferrara N, Haley B, Hegde P, James CD, Jubb A, Jurinka SS, Kaminker JS, Koeppen H, Kolumam G, Modrusan Z, Ozawa T, Phillips H, Scherer SJ, Schmidt M, Singh M, Stephan JP, Swain SM, Tam RN, Wu X, Yang SX, Yao J, Yeh RF, Yue P, Zhuang G DOI: http://dx.doi.org/10.1158/1078-0432.CCR-12-3635 Add to cart (remove)

Powered by Koha